Related references
Note: Only part of the references are listed.Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs
Chenglong Chen et al.
CANCER LETTERS (2021)
Association of IDH mutation and 1p19q co-deletion with tumor immune microenvironment in lower-grade glioma
Wanzun Lin et al.
MOLECULAR THERAPY-ONCOLYTICS (2021)
The presence of tumour-infiltrating lymphocytes (TILs) and the ratios between different subsets serve as prognostic factors in advanced hypopharyngeal squamous cell carcinoma
Jie Wang et al.
BMC CANCER (2020)
TYROBP is a potential prognostic biomarker of clear cell renal cell carcinoma
Ping Wu et al.
FEBS OPEN BIO (2020)
Identification ofTYROBPandC1QBas Two Novel Key Genes With Prognostic Value in Gastric Cancer by Network Analysis
Junjie Jiang et al.
FRONTIERS IN ONCOLOGY (2020)
Radiation-induced small extracellular vesicles as carriages promote tumor antigen release and trigger antitumor immunity
Wanzun Lin et al.
THERANOSTICS (2020)
Cancer immunoediting and resistance to T cell-based immunotherapy
Jake S. O'Donnell et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Diego Chowell et al.
SCIENCE (2018)
CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy
Ryuma Tokunaga et al.
CANCER TREATMENT REVIEWS (2018)
Understanding osteosarcomas
Emily Simpson et al.
JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS (2018)
Classification of triple-negative breast cancers based on Immunogenomic profiling
Yin He et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
Osteosarcoma of the jaw: Challenges in the diagnosis and treatment
Mohamed Atef ElKordy et al.
JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE (2018)
Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
Leisha A. Emens et al.
EUROPEAN JOURNAL OF CANCER (2017)
Tumour infiltrating lymphocytes correlate with improved survival in patients with esophageal squamous cell carcinoma
Dongxian Jiang et al.
SCIENTIFIC REPORTS (2017)
The Prognostic Value of Tumor-infiltrating Lymphocytes in Hepatocellular Carcinoma: a Systematic Review and Meta-analysis
Wei Yao et al.
SCIENTIFIC REPORTS (2017)
The Nature of Selection on the Major Histocompatibility Complex
Victor Apanius et al.
CRITICAL REVIEWS IN IMMUNOLOGY (2017)
CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer
Holger Bronger et al.
BRITISH JOURNAL OF CANCER (2016)
The urgent need to recover MHC class I in cancers for effective immunotherapy
Federico Garrido et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
Douglas B. Johnson et al.
NATURE COMMUNICATIONS (2016)
T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities
Zhan Wang et al.
FRONTIERS IN IMMUNOLOGY (2016)
Review of Osteosarcoma and Current Management
Ryan A. Durfee et al.
RHEUMATOLOGY AND THERAPY (2016)
DAP12-Based Activating Chimeric Antigen Receptor for NK Cell Tumor Immunotherapy
Katrin Toepfer et al.
JOURNAL OF IMMUNOLOGY (2015)
Emerging roles for platelets as immune and inflammatory cells
Craig N. Morrell et al.
BLOOD (2014)
Translational biology of osteosarcoma
Maya Kansara et al.
NATURE REVIEWS CANCER (2014)
Breast Cancer Expression of DAP12 is Associated With Skeletal and Liver Metastases and Poor Survival
Ivan Shabo et al.
CLINICAL BREAST CANCER (2013)
Cancer immunotherapy
Constantin N. Baxevanis et al.
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES (2009)
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
David A. Barbie et al.
NATURE (2009)
The major histocompatibility complex origin
E Danchin et al.
IMMUNOLOGICAL REVIEWS (2004)
Expression of invariant chain (CD 74) and major histocompatibility complex (MHC) class II antigens in the human fetus
S Badve et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2002)
Cutting edge: Signal-regulatory protein beta 1 is a DAP12-associated activating receptor expressed in myeloid cells
J Dietrich et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
